Zobrazeno 1 - 10 of 478 pro vyhledávání: '"Kinzel, O."'
1
Akademický článek
Structure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 Inhibitors.
Autor: Lucas SCC; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Blackwell JH; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Börjesson U; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Hargreaves D; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Milbradt AG; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Bostock MJ; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ahmed S; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beaumont K; DMPK, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cheung T; Oncology Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Demanze S; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Gohlke A; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Guerot C; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Haider A; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Kantae V; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Kauffman GW; Medicinal Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Kinzel O; Medicinal Chemistry, Oncology R&D, Acerta B.V., a Member of the AstraZeneca Group, Oss 5349, The Netherlands., Kupcova L; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Lainchbury MD; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Lamb ML; Medicinal Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Leon L; Oncology Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Palisse A; Medicinal Chemistry, Oncology R&D, Acerta B.V., a Member of the AstraZeneca Group, Oss 5349, The Netherlands., Sacchetto C; Bioscience, Oncology R&D, Acerta B.V., a Member of the AstraZeneca Group, Oss 5349, The Netherlands., Storer RI; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Su N; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Thomson C; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Vales J; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Chen Y; Pharmaron Beijing Co., Ltd., Beijing 100176, P. R. China., Hu X; Pharmaron Beijing Co., Ltd., Beijing 100176, P. R. China.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Sep 26; Vol. 67 (18), pp. 16455-16479. Date of Electronic Publication: 2024 Sep 18.
Zobrazit plný text záznamu
2
Akademický článek
Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen.
Autor: Lucas SCC; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Blackwell JH; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Börjesson U; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Hargreaves D; Mechanistic and Structural Biology, Discovery Sciences, R&DAstraZeneca, Cambridge CB2 0AA, U.K., Milbradt AG; Mechanistic and Structural Biology, Discovery Sciences, R&DAstraZeneca, Cambridge CB2 0AA, U.K., Ahmed S; Discovery Biology, Discovery Sciences, R&DAstraZeneca, Cambridge CB2 0AA, U.K., Bostock MJ; Mechanistic and Structural Biology, Discovery Sciences, R&DAstraZeneca, Cambridge CB2 0AA, U.K., Guerot C; Medicinal Chemistry, Oncology, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Gohlke A; Mechanistic and Structural Biology, Discovery Sciences, R&DAstraZeneca, Cambridge CB2 0AA, U.K., Kinzel O; Medicinal Chemistry, Oncology, R&D, Acerta B.V., a member of the AstraZeneca Group, Oss 5349, The Netherlands., Lamb ML; Medicinal Chemistry, Oncology, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Selmi N; Compound Synthesis and Management, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Stubbs CJ; Mechanistic and Structural Biology, Discovery Sciences, R&DAstraZeneca, Cambridge CB2 0AA, U.K., Su N; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Su Q; Medicinal Chemistry, Oncology, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Luo H; Pharmaron Beijing Co., Ltd., Beijing 100176, P. R. China., Xiong T; Pharmaron Beijing Co., Ltd., Beijing 100176, P. R. China., Zuo X; Pharmaron Beijing Co., Ltd., Beijing 100176, P. R. China., Bazzaz S; X-Chem Inc., Waltham, Massachusetts 02453, United States., Bienstock C; X-Chem Inc., Waltham, Massachusetts 02453, United States., Centrella PA; X-Chem Inc., Waltham, Massachusetts 02453, United States., Denton KE; X-Chem Inc., Waltham, Massachusetts 02453, United States., Gikunju D; X-Chem Inc., Waltham, Massachusetts 02453, United States., Guié MA; X-Chem Inc., Waltham, Massachusetts 02453, United States., Guilinger JP; X-Chem Inc., Waltham, Massachusetts 02453, United States., Hupp C; X-Chem Inc., Waltham, Massachusetts 02453, United States., Keefe AD; X-Chem Inc., Waltham, Massachusetts 02453, United States., Satoh T; X-Chem Inc., Waltham, Massachusetts 02453, United States., Zhang Y; X-Chem Inc., Waltham, Massachusetts 02453, United States., Rivers EL; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2024 May 20; Vol. 15 (6), pp. 791-797. Date of Electronic Publication: 2024 May 20 (Print Publication: 2024).
Zobrazit plný text záznamu
3
Akademický článek
Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease.
Autor: Hollenback D; Gilead Sciences, Inc, United States., Hambruch E; Biology, Phenex Pharmceuticals, Germany., Fink G; Biology, Phenex Pharmceuticals, Germany., Birkel M; Biology, Phenex Pharmceuticals, Germany., Schulz A; Biology, Phenex Pharmceuticals, Germany., Hornberger M; Biology, Phenex Pharmceuticals, Germany., Liu K; Biology, Gilead Sciences, Inc, United States., Staiger KM; Drug Metabolism and Pharmacokinetics, Gilead Sciences, United States., Krol HD; Biology, Phenex Pharmceuticals, Germany., Deuschle U; Biology, Phenex Pharmceuticals, Germany., Steeneck C; Biology, Phenex Pharmceuticals, Germany., Kinzel O; Biology, Phenex Pharmceuticals, Germany., Liles JT; Biology, Gilead Sciences, Inc, United States., Budas G; Biology, Gilead Sciences, Inc, United States., Watkins WJ; Biology, Gilead Sciences, Inc, United States., Kremoser C; Biology, Phenex Pharmceuticals, Germany cm.kremoser@wm-therapeutics.com.
Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2024 Feb 26. Date of Electronic Publication: 2024 Feb 26.
Zobrazit plný text záznamu
4
Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
Autor: Xue X; Janssen Research & Development, LLC, La Jolla, CA, USA. xxue@its.jnj.com., De Leon-Tabaldo A; Janssen Research & Development, LLC, La Jolla, CA, USA., Luna-Roman R; Janssen Research & Development, LLC, La Jolla, CA, USA., Castro G; Janssen Research & Development, LLC, Spring House, PA, USA., Albers M; Department of Research, Phenex Pharmaceuticals AG, Heidelberg, Germany., Schoetens F; Janssen Research & Development, LLC, La Jolla, CA, USA., DePrimo S; Janssen Research & Development, LLC, La Jolla, CA, USA., Devineni D; Janssen Research & Development, LLC, Spring House, PA, USA., Wilde T; Janssen Research & Development, LLC, Spring House, PA, USA., Goldberg S; Janssen Research & Development, LLC, La Jolla, CA, USA., Kinzel O; Department of Research, Phenex Pharmaceuticals AG, Heidelberg, Germany., Hoffmann T; Department of Research, Phenex Pharmaceuticals AG, Heidelberg, Germany., Fourie AM; Janssen Research & Development, LLC, La Jolla, CA, USA., Thurmond RL; Janssen Research & Development, LLC, La Jolla, CA, USA. RTHURMON@its.jnj.com.
Publikováno v: Scientific reports [Sci Rep] 2022 Apr 06; Vol. 12 (1), pp. 5740. Date of Electronic Publication: 2022 Apr 06.
Zobrazit plný text záznamu
5
Akademický článek
Synthesis and biological evaluation of a pyoverdin-β-lactam conjugate: a new type of arginine-specific cross-linking in aqueous solution.
Autor: Kinzel, O.1, Budzikiewicz, H.1
Publikováno v: Journal of Peptide Research. Jul99, Vol. 53 Issue 6, p618-625. 8p.
Zobrazit plný text záznamu
6
Akademický článek
Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
Autor: Xue X; Janssen Research & Development, LLC, La Jolla, CA, USA. xxue@its.jnj.com., De Leon-Tabaldo A; Janssen Research & Development, LLC, La Jolla, CA, USA., Luna-Roman R; Janssen Research & Development, LLC, La Jolla, CA, USA., Castro G; Janssen Research & Development, LLC, Spring House, PA, USA., Albers M; Department of Research, Phenex Pharmaceuticals AG, Heidelberg, Germany., Schoetens F; Janssen Research & Development, LLC, La Jolla, CA, USA., DePrimo S; Janssen Research & Development, LLC, La Jolla, CA, USA., Devineni D; Janssen Research & Development, LLC, Spring House, PA, USA., Wilde T; Janssen Research & Development, LLC, Spring House, PA, USA., Goldberg S; Janssen Research & Development, LLC, La Jolla, CA, USA., Kinzel O; Department of Research, Phenex Pharmaceuticals AG, Heidelberg, Germany., Hoffmann T; Department of Research, Phenex Pharmaceuticals AG, Heidelberg, Germany., Fourie AM; Janssen Research & Development, LLC, La Jolla, CA, USA., Thurmond RL; Janssen Research & Development, LLC, La Jolla, CA, USA. RTHURMON@its.jnj.com.
Publikováno v: Scientific reports [Sci Rep] 2021 May 26; Vol. 11 (1), pp. 11066. Date of Electronic Publication: 2021 May 26.
Zobrazit plný text záznamu
7
Akademický článek
Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments.
Autor: Gabrielli, Filippo1,2 (AUTHOR) gabrielli.filippo@unimore.it, Crepaldi, Eleonora3 (AUTHOR), Cavicchioli, Alessia2 (AUTHOR), Rivi, Marco3 (AUTHOR), Costanzo, Arianna Carmen4 (AUTHOR), Cursaro, Carmela1 (AUTHOR), Andreone, Pietro1,2,3 (AUTHOR)
Publikováno v: Biomolecules (2218-273X). Oct2024, Vol. 14 Issue 10, p1227. 37p.
Zobrazit plný text záznamu
8
Akademický článek
Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold.
Autor: Kinzel O; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany. Electronic address: acr8172@gmail.com., Steeneck C; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany. Electronic address: c.steeneck@t-online.de., Anderhub S; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Hornberger M; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Pinto S; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Morschhaeuser B; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Albers M; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Sonnek C; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Wang Y; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Mallinger A; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Czekańska M; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Hoffmann T; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2021 Feb 01; Vol. 33, pp. 127738. Date of Electronic Publication: 2020 Dec 11.
Zobrazit plný text záznamu
9
Akademický článek
Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.
Autor: Steeneck C; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany. Electronic address: c.steeneck@t-online.de., Kinzel O; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Anderhub S; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Hornberger M; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Pinto S; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Morschhaeuser B; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Albers M; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Sonnek C; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Czekańska M; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany., Hoffmann T; Phenex Pharmaceuticals AG, Waldhofer Str. 104, 69123 Heidelberg, Germany.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2021 Feb 01; Vol. 33, pp. 127744. Date of Electronic Publication: 2020 Dec 15.
Zobrazit plný text záznamu
10
Akademický článek
Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.
Autor: Gege C; Phenex Pharmaceuticals AG, Waldhofer Strasse 104, 69123 Heidelberg, Germany. Electronic address: christian.gege@web.de., Albers M; Phenex Pharmaceuticals AG, Waldhofer Strasse 104, 69123 Heidelberg, Germany., Kinzel O; Phenex Pharmaceuticals AG, Waldhofer Strasse 104, 69123 Heidelberg, Germany., Kleymann G; Phenex Pharmaceuticals AG, Waldhofer Strasse 104, 69123 Heidelberg, Germany., Schlüter T; Phenex Pharmaceuticals AG, Waldhofer Strasse 104, 69123 Heidelberg, Germany., Steeneck C; Phenex Pharmaceuticals AG, Waldhofer Strasse 104, 69123 Heidelberg, Germany., Hoffmann T; Phenex Pharmaceuticals AG, Waldhofer Strasse 104, 69123 Heidelberg, Germany., Xue X; Janssen Research and Development, LLC, San Diego, CA 92121, USA., Cummings MD; Janssen Research and Development, Spring House, PA 19477, USA., Spurlino J; Janssen Research and Development, Spring House, PA 19477, USA., Milligan C; Janssen Research and Development, Spring House, PA 19477, USA., Fourie AM; Janssen Research and Development, LLC, San Diego, CA 92121, USA., Edwards JP; Janssen Research and Development, LLC, San Diego, CA 92121, USA., Leonard K; Janssen Research and Development, Spring House, PA 19477, USA., Coe K; Janssen Research and Development, LLC, San Diego, CA 92121, USA., Scott B; Janssen Research and Development, LLC, San Diego, CA 92121, USA., Pippel D; Janssen Research and Development, LLC, San Diego, CA 92121, USA., Goldberg SD; Janssen Research and Development, LLC, San Diego, CA 92121, USA. Electronic address: sgoldbe1@its.jnj.com.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2020 Jun 15; Vol. 30 (12), pp. 127205. Date of Electronic Publication: 2020 Apr 21.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje